Terms: = Breast cancer AND CARS, P49589, 833, ENSG00000110619
317 results:
1. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract] [Full Text] [Related]
2. Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.
Wang Y; Li Y; Jiang H; Zuo C; Xu W
Br J Radiol; 2024 Jan; 97(1153):237-248. PubMed ID: 38263821
[TBL] [Abstract] [Full Text] [Related]
3. Endogenous Signaling Molecule Activating (ESMA) cars: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative breast cancer.
Ebbinghaus M; Wittich K; Bancher B; Lebedeva V; Appelshoffer A; Femel J; Helm MS; Kollet J; Hardt O; Pfeifer R
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203786
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic accuracy of the breast MRI Kaiser score in suspected architectural distortions and its comparison with mammography.
Aslan O; Oktay A
Sci Rep; 2024 Jan; 14(1):447. PubMed ID: 38172557
[TBL] [Abstract] [Full Text] [Related]
5. cancer incidence in Iran in 2016: A study based on the Iranian National cancer Registry.
Hadavandsiri F; Allahqoli L; Rahimi Y; Salehiniya H; Ghazanfari Savadkoohi E; Akbari ME
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1967. PubMed ID: 38148563
[TBL] [Abstract] [Full Text] [Related]
6. Rationale, Procedures, and Response Rates for a Pilot Study to Sample cancer Survivors for NCI's Health Information National Trends Survey: HINTS-SEER 2021.
Blake KD; Moser RP; Murray AB; Davis T; Cantor D; Caporaso A; West M; Bentler S; McKinley M; Shariff-Marco S; Wiggins C; Vanderpool RC
J Health Commun; 2024 Feb; 29(2):119-130. PubMed ID: 38131342
[TBL] [Abstract] [Full Text] [Related]
7. Quality of Life in breast cancer Patients Treated With Mistletoe Extracts: A Systematic Review and Meta-Analysis.
Loef M; Paepke D; Walach H
Integr Cancer Ther; 2023; 22():15347354231198074. PubMed ID: 37888846
[TBL] [Abstract] [Full Text] [Related]
8. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
[TBL] [Abstract] [Full Text] [Related]
9. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
[TBL] [Abstract] [Full Text] [Related]
10. The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.
Zhou L; Wu J; Ruan M; Xiao Y; Lan H; Wu Q; Yu CW; Zhang Q
Breast Cancer Res; 2023 Oct; 25(1):115. PubMed ID: 37794509
[TBL] [Abstract] [Full Text] [Related]
11. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung cancer With Epidermal Growth Factor Receptor Mutation.
Zhao KX; Zhang YF; Zheng L; Pan YF; He ZH
Am J Clin Oncol; 2023 Dec; 46(12):551-558. PubMed ID: 37779240
[TBL] [Abstract] [Full Text] [Related]
12. Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy.
Jin Y; Lan A; Dai Y; Jiang L; Liu S
Eur J Med Res; 2023 Sep; 28(1):394. PubMed ID: 37777809
[TBL] [Abstract] [Full Text] [Related]
13. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative breast cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of breast cancer malignancy, prognostic factors and molecular subtypes using a continuous-time random-walk MR diffusion model.
Chang H; Wang D; Li Y; Xiang S; Yang YX; Kong P; Fang C; Ming L; Wang X; Zhang C; Jia W; Yan Q; Liu X; Zeng Q
Eur J Radiol; 2023 Sep; 166():111003. PubMed ID: 37506477
[TBL] [Abstract] [Full Text] [Related]
15. Expanding Scope About Factors Influencing Seroma Formation After breast cancer Surgery.
Eldamshety O; Lamey A; Ismail KA; Esmail T; Tolba M; Elmoneim Mahmoud R
J Pak Med Assoc; 2023 Apr; 73(Suppl 4)(4):S282-S286. PubMed ID: 37482873
[TBL] [Abstract] [Full Text] [Related]
16. Voluntary Deep Inspiration Breath-Hold (VDIBH) Whole-breast Irradiation Assisted by Optical Surface Monitoring System (OSMS) in Patients With Left-Sided breast cancer: A Prospective Phase II Study.
Zhang JH; Li TT; Qin SR; Liu ZQ; Chen SY; Song YW; Tang Y; Jing H; Fang H; Zhao XR; Jin J; Liu YP; Tang Y; Qi SN; Li N; Chen B; Lu NN; Li YX; Wang SL
Technol Cancer Res Treat; 2023; 22():15330338231173773. PubMed ID: 37312511
[No Abstract] [Full Text] [Related]
17. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative breast cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
[TBL] [Abstract] [Full Text] [Related]
18. Advances in natural killer cell therapies for breast cancer.
Kiaei SZF; Nouralishahi A; Ghasemirad M; Barkhordar M; Ghaffari S; Kheradjoo H; Saleh M; Mohammadzadehsaliani S; Molaeipour Z
Immunol Cell Biol; 2023 Sep; 101(8):705-726. PubMed ID: 37282729
[TBL] [Abstract] [Full Text] [Related]
19. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.
Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
[TBL] [Abstract] [Full Text] [Related]
20. mTOR pathway candidate genes and energy intake interaction on breast cancer risk in Black women from the Women's Circle of Health Study.
Ilozumba MN; Yaghjyan L; Datta S; Zhao J; Hong CC; Lunetta KL; Zirpoli G; Bandera EV; Palmer JR; Yao S; Ambrosone CB; Cheng TD
Eur J Nutr; 2023 Sep; 62(6):2593-2604. PubMed ID: 37209192
[TBL] [Abstract] [Full Text] [Related]
[Next]
